NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Is a
Allocation Type
Non-Randomized
0
Health Conditions in Trial
Intervention Model
Sequential Assignment
0
Intervention Name
NKTR-255 Q21
0
NKTR-255
0
Daratumumab
0
Rituximab
0
Interventional Trial Phase
Phase 1
0
Interventional Trial Purpose
Treatment
0
Intervention Type
Drug
0
Last Updated
June 15, 2023
0
Masking Type
None (Open Label)
0
Primary Completion Date
April 24, 2023
0
Trial Recruitment Size
30
0
Trial Sponsor
Clinical Trial Start Date
October 7, 2019
0
Study Completion Date
April 24, 2023
0
Clinical Trial Study Type
Interventional
0
NCT Number
Official Name
A Phase 1, Open-label, Multi-center, Dose Escalation and Dose Expansion Study of NKTR-255 in Relapsed or Refractory Hematological Malignancies
0
Official Website
Find more entities like NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.